Wockhardt (NSE:WOCKPHARMA) Construction In Progress: ₹6,710 Mil (As of Mar. 2026)


NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
66 GF Score
Price ₹1,810.70
GF Value ₹1,267.68
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Wockhardt Construction In Progress?

Wockhardt NSE:WOCKPHARMA -1.12% 66 Construction In Progress is ₹6,710 Mil as of Mar. 2026. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 66/100 and a GF Value™ of ₹1,267.68 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Wockhardt's quarterly construction in progress declined from Sep. 2025 (₹5,830 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹6,710 Mil).

Wockhardt's annual construction in progress increased from Mar. 2024 (₹4,430 Mil) to Mar. 2025 (₹5,230 Mil) and increased from Mar. 2025 (₹5,230 Mil) to Mar. 2026 (₹6,710 Mil).

Wockhardt Construction In Progress Historical Data

* Premium members only.

The historical data trend for Wockhardt's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wockhardt Construction In Progress Chart

Wockhardt Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,990.00 4,260.00 4,430.00 5,230.00 6,710.00

Wockhardt Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,230.00 0.00 5,830.00 0.00 6,710.00
NSE:WOCKPHARMA
66GF Score
Wockhardt Ltd NSE:WOCKPHARMA
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wockhardt Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹6,710 Mil mean?
Wockhardt (NSE:WOCKPHARMA) has a Construction In Progress of ₹6,710 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Wockhardt and its competitors.
Is Wockhardt's Construction In Progress too high?
Wockhardt's current Construction In Progress is ₹6,710 Mil. Overall, Wockhardt has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Construction In Progress compare to ZTS and UTHR?
Wockhardt's Construction In Progress of ₹6,710 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Wockhardt and its competitors. Wockhardt's current Construction In Progress is ₹6,710 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,267.68, compared to a current price of ₹1,810.70 — trading 42.8% above its estimated fair value. The current Construction In Progress is ₹6,710 Mil. Wockhardt's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Construction In Progress is ₹6,710 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹1,810.70 is trading 42.8% above its estimated GF Value™ of ₹1,267.68. GuruFocus considers Wockhardt to be Significantly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • Construction In Progress: ₹6,710 Mil
  • GF Value™: ₹1,267.68 vs. price of ₹1,810.70 (42.8% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
66GF Score

Get the complete analysis for NSE:WOCKPHARMA

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,810.70
Price
₹1,267.68
GF Value